A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD | MicrobiomeTrials← Back to trialsNCT07038200
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2025-06-10Est. Completion: 2028-05
Enrollment target: 200 participants Locations- University of California Irvine, Orange, California, United States
- Stanford University, Palo Alto, California, United States
- University of Colorado, Denver, Colorado, United States
- University of Florida, Gainesville, Florida, United States
- University of Iowa, Iowa City, Iowa, United States
- Kansas University Medical Center, Kansas City, Kansas, United States
- Kennedy Krieger Institute, Baltimore, Maryland, United States
- University of Massachusetts, Worcester, Massachusetts, United States
- University of Rochester Medical Center, Rochester, New York, United States
- Duke University, Durham, North Carolina, United States
- Ohio State University, Columbus, Ohio, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
- Virginia Commonwealth University, Richmond, Virginia, United States
- University of Calgary - Cumming School of Medicine, Calgary, Alberta, Canada
- University of Alberta Hospital, Edmonton, Alberta, Canada
Other microbiome trials you might be interested in
Facioscapulohumeral Muscular Dystrophy
The goal of this clinical trial is to learn how safe and tolerable EPI-321 is and whether there may be early signs it is…
Los Angeles, United StatesEst. completion Jul 7, 2027
FSHDFSHD1FSHD2FMDFMD2Fascioscapulohumeral Muscular DystrophyFascioscapulohumeral Muscular Dystrophy Type 1Fascioscapulohumeral Muscular Dystrophy Type 2
The Ottawa Hospital, Ottawa, Ontario, CanadaGenge Partners Inc, Montreal, Quebec, CanadaAarhus University Hospital, Aarhus, DenmarkRigshospitalet, Copenhagen, DenmarkCentre de Reference des Maladies Neuromusculaires et de la SLA - AP-HM Hopital de La Timone, Marseille, FranceCHU de Montpellier - Hopital Gui de Chauliac, Montpellier, FranceCHU de Nice - Hopital Pasteur 2 - Centre de reference des Maladies Neuromusculaires, Nice, FranceAP-HP Hopital Pitie-Salpetriere, Paris, FranceUniversitaetsklinikum Bonn, Bonn, GermanyGeorg-August-Universitaet Goettingen Stiftung oeffentlichen Rechts Universitaetsmedizin Goettingen, Göttingen, GermanyKlinikum der Ludwig-Maximilians-Universitaet Muenchen, München, GermanyUniversitaetsklinikum Ulm, Ulm, GermanyFondazione Serena ETS - Centro Clinico NeMO Milano, Milan, ItalyAzienda Ospedaliero Universitaria Pisana, Pisa, ItalyAzienda Ospedaliero-Universitaria Sant'Andrea, Roma, ItalyFondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore, Roma, ItalyNational Hospital Organization Osaka Toneyama Medical Center, Osaka, JapanThe University of Osaka Hospital, Osaka, JapanNational Hospital Organization Sendai Nishitaga Hospital, Sendai, JapanNational Center of Neurology and Psychiatry, Tokyo, JapanAcademisch Ziekenhuis Leiden, Leiden, NetherlandsStichting Radboud Universitair Medisch Centrum, Nijmegen, NetherlandsHospital Universitari de Bellvitge, Barcelona, SpainHospital Universitario Vall d'Hebron, Barcelona, SpainHospital Universitario Donostia, San Sebastián, SpainHospital Universitari i Politecnic La Fe, Valencia, SpainNational Hospital for Neurology & Neurosurgery, London, United KingdomSt. George's University Hospitals NHS Foundation Trust, London, United KingdomRoyal Victoria Infirmary, Newcastle upon Tyne, United KingdomRoyal Hallamshire Hospital, Sheffield, United KingdomDystrophies, Facioscapulohumeral Muscular
Dystrophy, Facioscapulohumeral Muscular
Facioscapulohumeral Muscular Dystrophy 1
Facioscapulohumeral Muscular Dystrophy 2
Facio-Scapulo-Humeral Dystrophy
Atrophy, Facioscapulohumeral
Atrophies, Facioscapulohumeral
Facioscapulohumeral Atrophy
Muscular Dystrophies
Muscular Dystrophy, Facioscapulohumeral
FSH Muscular Dystrophy
Landouzy Dejerine Dystrophy
Landouzy-Dejerine Muscular Dystrophy
Dystrophies, Landouzy-Dejerine
Dystrophy, Landouzy-Dejerine
Landouzy-Dejerine Syndrome
Muscular Dystrophy, Landouzy Dejerine
Progressive Muscular Dystrophy
FSH
A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, …
Los Angeles, United StatesCompleted Mar 18, 2026